Pegasys® in Patients With Myeloproliferative Diseases
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to see if Pegasys (IFN-alpha2a) can help to
control the disease in patients with ET, PV, AMM/MF, and Ph-negative CML. The safety of this
treatment will also be studied.